Current status of coronary artery bypass grafting

被引：24
作者：
Kobayashi J. [1 ]
机构：
[1] Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka 565-8565
来源：
General Thoracic and Cardiovascular Surgery | 2008年 / 56卷 / 6期
关键词：
Coronary artery bypass; Percutaneous coronary intervention;
D O I：
10.1007/s11748-008-0251-x
中图分类号：
学科分类号：
摘要：
The number of cases of coronary artery bypass grafting (CABG) reached more than 21 000 in Japan in 2002, and the operative mortality decreased to less than 1%, including emergency operations. The annual number of CABGs in Japan declined 17% after 2003 to 18 000 cases in 2005 owing to unrestricted percutaneous coronary intervention (PCI) with drug-eluting stents. However, CABG is the best treatment for multivessel coronary artery disease based on the comparative data of PCI versus CABG. There have been two trends in CABG during the last decade. One is the widespread use of off-pump (OP) CABG, and the other is multiple coronary artery revascularization. In 2004 and 2005, approximately 60% of all isolated CABG procedures in Japan were performed without cardiopulmonary bypass. In a study of long-term outcomes comparing PCI with drugeluting stents versus CABG with only arterial grafts, the latter was carried out in 52% of total cases and in 66% of OPCAB cases. OPCAB with multiple arterial grafts has become the standard CABG in Japan. © 2008 The Japanese Association for Thoracic Surgery.
引用
收藏
页码：260 / 267
页数：7
相关论文
共 93 条
[1]  
King III S.B., Lebbro N.J., Weintraub W.S., Kosinski A.S., Barnhart H.X., Kutner M.H., Et al., A randomized trial comparing coronary angioplasty with coronary bypass surgery
[2]  
Emory Angioplasty versus Surgery Trial (EAST), N Engl J Med, 331, pp. 1044-1050, (1994)
[3]  
King III S.B., Kosinski A.S., Guyton R.A., Lembro N.J., Weintraub W.S., Eight-year mortality in the Emory Angioplasty versus Surgery trial (EAST), J Am Coll Cardiol, 35, pp. 1116-1121, (2000)
[4]  
Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease, N Engl J Med, 335, pp. 217-225, (1996)
[5]  
Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status, J Am Coll Cardiol, 35, pp. 1122-1129, (2000)
[6]  
King S.B., Kosinski A.S., Guyton R.A., Lembo N.J., Weintraub W.S., Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST), J Am Coll Cardiol, 35, pp. 1116-1121, (2000)
[7]  
Hoffman S.N., Ten Brrook J.A., Wolf M.P., Pauker S.G., Salem D.N., Wong J.B., A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal angioplasty: One-to eight-year outcomes, J Am Coll Cardiol, 41, pp. 1293-1304, (2003)
[8]  
Serruys P.W., Ong A.T.L., Van Herwerden L.A., Sousa J.E., Jatene A., Bonnier J.J., Et al., Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial, J Am Coll Cardiol, 46, pp. 575-581, (2005)
[9]  
Serruys P.W., Unger F., Sousa J.E., Jatene A., Bonnier H.J., Schonberger J.P., Et al., Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease, N Engl J Med, 344, pp. 1117-1124, (2001)
[10]  
Guyton R.A., Coronary artery bypass is superior to drugeluting stents in multivessel coronary artery disease, Ann Thorac Surg, 81, pp. 1949-1957, (2006)
12345678910